251 related articles for article (PubMed ID: 30266819)
1. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
[TBL] [Abstract][Full Text] [Related]
2. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
3. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
4. Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Jenkins TW; Downey-Kopyscinski SL; Fields JL; Rahme GJ; Colley WC; Israel MA; Maksimenko AV; Fiering SN; Kisselev AF
Sci Rep; 2021 May; 11(1):10883. PubMed ID: 34035431
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
6. Site-Specific Proteasome Inhibitors.
Kisselev AF
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053202
[TBL] [Abstract][Full Text] [Related]
7. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
Niewerth D; Franke NE; Jansen G; Assaraf YG; van Meerloo J; Kirk CJ; Degenhardt J; Anderl J; Schimmer AD; Zweegman S; de Haas V; Horton TM; Kaspers GJ; Cloos J
Haematologica; 2013 Dec; 98(12):1896-904. PubMed ID: 24056819
[TBL] [Abstract][Full Text] [Related]
8. Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells.
Woodle ES; Tremblay S; Brailey P; Girnita A; Alloway RR; Aronow B; Dasgupta N; Ebstein F; Kloetzel PM; Lee MJ; Kim KB; Singh H; Driscoll JJ
Am J Transplant; 2020 Feb; 20(2):399-410. PubMed ID: 31595669
[TBL] [Abstract][Full Text] [Related]
9. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
10. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
[TBL] [Abstract][Full Text] [Related]
11. A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities.
de Bruin G; Xin BT; Kraus M; van der Stelt M; van der Marel GA; Kisselev AF; Driessen C; Florea BI; Overkleeft HS
Angew Chem Int Ed Engl; 2016 Mar; 55(13):4199-203. PubMed ID: 26511210
[TBL] [Abstract][Full Text] [Related]
12. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.
Pletinckx K; Vaßen S; Schlusche I; Nordhoff S; Bahrenberg G; Dunkern TR
Pharmacol Res Perspect; 2019 Aug; 7(4):e00482. PubMed ID: 31236277
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Design of Fluorogenic Substrates Selective for Human Proteasome Subunits.
Maurits E; Degeling CG; Kisselev AF; Florea BI; Overkleeft HS
Chembiochem; 2020 Nov; 21(22):3220-3224. PubMed ID: 32598532
[TBL] [Abstract][Full Text] [Related]
15. The immunoproteasome as a target in hematologic malignancies.
Kuhn DJ; Orlowski RZ
Semin Hematol; 2012 Jul; 49(3):258-62. PubMed ID: 22726549
[TBL] [Abstract][Full Text] [Related]
16. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits.
Xin BT; Huber EM; de Bruin G; Heinemeyer W; Maurits E; Espinal C; Du Y; Janssens M; Weyburne ES; Kisselev AF; Florea BI; Driessen C; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2019 Feb; 62(3):1626-1642. PubMed ID: 30657666
[TBL] [Abstract][Full Text] [Related]
18. Immunoproteasome Activity and Content Determine Hematopoietic Cell Sensitivity to ONX-0914 and to the Infection of Cells with Lentiviruses.
Vagapova E; Burov A; Spasskaya D; Lebedev T; Astakhova T; Spirin P; Prassolov V; Karpov V; Morozov A
Cells; 2021 May; 10(5):. PubMed ID: 34066177
[TBL] [Abstract][Full Text] [Related]
19. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
Besse L; Besse A; Kraus M; Maurits E; Overkleeft HS; Bornhauser B; Bourquin JP; Driessen C
Cells; 2021 Oct; 10(11):. PubMed ID: 34831075
[TBL] [Abstract][Full Text] [Related]
20. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
